GlassScriptPhysician profile
Burton P Sanders
NPI 1154491207
$18,576.59
in general payments reported to CMS, 2019-2025
60 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,894 · 2020: $2,405 · 2021: $3,066 · 2022: $2,967 · 2023: $2,318 · 2024: $3,148 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,580 · Consulting Fee: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,580.37 |
| Consulting Fee | $1,664.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,237.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,795.62 | 2019-2025 | Otezla, Repatha, Evenity |
| Regeneron Healthcare Solutions, INC. | $1,664.00 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,489.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,226.53 | 2019-2025 | |
| Lilly USA, LLC | $1,006.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $911.10 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Glaxosmithkline, LLC. | $897.84 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $842.20 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $588.97 | 2019-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $553.44 | 2019-2022 | |
| Astellas Pharma US INC | $541.97 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $411.46 | 2021-2025 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $388.52 | 2019-2024 | Spravato, Xarelto |
| Biohaven Pharmaceuticals, INC. | $279.11 | 2020-2021 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Burton Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.